Clinical trials: Asthma With Eosinophilic Phenotype
Asthma With Eosinophilic Phenotype
A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype
- Trial name
- NCT06653322
- Testing
- HR-1703
- Where
- China
- Volunteers
- 401 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Asthma
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\xa0The purpose of this study is to assess how depemokimab, a…
- Trial name
- NCT06979323
- Testing
- Depemokimab
- Where
- 50 sites in United States, Belgium and 10 more
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Asthma
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an…
- Trial name
- REIMAGINE (NCT06041386)
- Testing
- Mepolizumab, Spirometry
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study of Depemokimab in Participants of 6 to 11 Years of Age
This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age.
- Trial name
- GLIDE (NCT07671001)
- Testing
- Depemokimab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Asthma With Eosinophilic Phenotype
A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype.
- Trial name
- NCT05522439
- Testing
- SHR-1703
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Asthma in Children
Study for Children & Adolescent With Severe Asthma With an Eosinophilic Phenotype Treated With Mepolizumab
Open label, observational cohort study conducted to collect demographics, clinical characteristics and outcome observational data from children (6-17 years) with a clinical diagnosis of severe asthma in 2 countries (Spain and…
- Trial name
- CASAM (NCT05139381)
- Testing
- Mepolizumab
- Where
- United Kingdom
- Volunteers
- 148 people
- Sponsor
- King's College Hospital NHS Trust
COPD Asthma, Eosinophilic Asthma
Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
Around 1/3 of patients with COPD have elevated eosinophil levels. However, the role of eosinophils in COPD has not been yet understood and is probably different in COPD and in asthma.
- Trial name
- NCT05398133
- Where
- Poland
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Bronchial Asthma, Eosinophilic Asthma
XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma
A multicenter, double-blind, randomized, pilot study in parallel groups to assess the efficacy and safety of XC8 at a dose of 100 mg versus placebo over a 12-week treatment period in non-smoking patients with a confirmed…
- Trial name
- NCT04674137
- Testing
- XC8 100 mg
- Where
- 18 sites in Russia
- Volunteers
- 70 people
- Sponsor
- Chemlmmune Therapeutics LLC
Asthma
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically…
- Trial name
- NIMBLE (NCT04718389)
- Testing
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab
- Where
- 397 sites in United States, Australia and 19 more
- Volunteers
- 1,717 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma, Chronic Sinusitis
Eosinophils Endotypes in Chronic Airway Inflammatory Diseases
Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are frequently described as unified airway inflammatory diseases. Both heavily impacts quality of life with substantial productivity loss.
- Conditions
- Eosinophilic Asthma, Chronic Sinusitis, Eosinophilic Rhinitis
- Trial name
- PLEIAD (NCT04187976)
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Lille
Asthma
Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an…
- Trial name
- SWIFT-1 (NCT04719832)
- Testing
- GSK3511294 (Depemokimab)
- Where
- 123 sites in United States, Canada and 10 more
- Volunteers
- 395 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.
- Trial name
- SWIFT-2 (NCT04718103)
- Testing
- GSK3511294
- Where
- 129 sites in United States, Australia and 9 more
- Volunteers
- 397 people
- Sponsor
- GlaxoSmithKline
Asthma Persistent, Asthma, Allergic
Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
The aim of this study is to determine and compare serum cytokine levels of six different severe asthma inflammatory phenotypes differentiated by their atopy, peripheral eosinophilia and/or chronic rhinosinusitis and/or nasal…
- Conditions
- Asthma Persistent, Asthma, Allergic, Eosinophilic Asthma, Chronic Rhinosinusitis (Diagnosis)
- Trial name
- NCT03563521
- Where
- Turkey (Türkiye)
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- TC Erciyes University
In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India
FAsenra Safety Trial in India
Benralizumab is a humanised, afucosylated, monoclonal antibody that binds specifically to the human interlukin-5 (IL-5) receptor alpha subunit (IL-5Rα) of target cells such as eosinophils and basophils (Takatsu et al, 1994; Toba…
- Trial name
- FAST (NCT05384938)
- Testing
- Benralizumab
- Where
- 13 sites in India
- Volunteers
- 139 people
- Sponsor
- AstraZeneca
Asthma
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic…
- Trial name
- AGILE (NCT05243680)
- Testing
- GSK3511294 (Depemokimab)
- Where
- 137 sites in United States, Australia and 12 more
- Volunteers
- 641 people
- Sponsor
- GlaxoSmithKline
Asthma With Eosinophilic Phenotype
A Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants
This is a single-center, randomized, parallel-group, open-label clinical study designed to compare the bioavailability and safety of SHR-1703 Injection administered subcutaneously using a pre-filled safety syringe (PFS) or a…
- Trial name
- NCT07701239
- Testing
- SHR-1703 Injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Asthma, Eosinophilic Asthma
Intense Airway Eosinophilia in Asthma
In asthma, the type and importance of the inflammatory response in the airways has allows identification of different phenotypes.
- Trial name
- NCT03696914
- Where
- Canada
- Volunteers
- 918 people
- Sponsor
- Laval University